Plasma asymmetric dimethylarginine and retinal vessel diameters in middle-aged men

Metabolism: Clinical and Experimental

Volumn 56, Issue 10, 2007, Pages 1305-1310

  Hemminki, Virpi ^a   Laakso, Juha ^b   Kähönen, Mika ^a,c   Turjanmaa, Väinö ^a,c   Uusitalo, Hannu ^a,c   Lehtimäki, Terho ^a,c   Ruokonen, Inkeri ^d   Laaksonen, Reijo ^c,d   Huhtala, Heini ^e   Päivä, Hannu ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b NATL VET AND FOOD RES INSTITUTE   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR;

ADULT; ARTERIOLE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD VESSEL DIAMETER; BLOOD VESSEL REACTIVITY; EYE FUNDUS; EYE PHOTOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; OPTIC DISK; PRIORITY JOURNAL; RETINA ARTERY; RETINA BLOOD VESSEL; RISK FACTOR; TANDEM MASS SPECTROMETRY; VENULE;

ADULT; ARGININE; ARTERIOLES; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYPERTENSION; LINEAR MODELS; LIPIDS; MALE; MIDDLE AGED; RETINAL VESSELS; SMOKING; TANDEM MASS SPECTROMETRY; VASCULAR RESISTANCE; VENULES;

EID: 34548662469     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.05.012     Document Type: Article

References (34)

1. Hubbard L.D., Brothers B.S., King W.N., Clegg L.X., et al. Methods for evaluating of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 106 (1999) 2269-2280
2. Klein R., Sharrett A.R., Klein B.E., et al. Are retinal arteriolar abnormalities related to atherosclerosis? The Atherosclerosis Risk in Communities Study. Arterioscler Thromb Vasc Biol 20 (2000) 1644-1650
3. Wong T.Y., Klein R., Nieto F.J., et al. Retinal microvascular abnormalities and ten-year cardiovascular mortality. A population-based case-control study. Ophthalmology 110 (2003) 933-940
4. Ikram M.K., Witteman J.C.M., Vingerling J.R., et al. Retinal vessel diameters and risk of hypertension. The Rotterdam Study. Hypertension 47 (2006) 189-194
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1992) 801-809
6. Delles C., Michelson G., Harazny J., et al. Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke 35 (2004) 1289-1293
7. Michelson G., Warntges S., Harazny J., et al. Effect of NOS inhibition on retinal arterial and capillary circulation in early arterial hypertension. Retina 26 (2006) 437-444
8. Haefliger I.O., Flammer J., and Luscher T.F. Heterogeneity of endothelium-dependent regulation in ophthalmic and ciliary arteries. Invest Ophthalmol Vis Sci 34 (1993) 1722-1730
9. Toda N., Toda M., Ayajiki K., et al. Cholinergic nerve function in monkey ciliary arteries innervated by nitroxidergic nerve. Am J Physiol Heart Circ Physiol 274 (1998) H1582-H1589
10. Leiper J., and Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthase. Cardiovasc Res 43 (1999) 542-548
11. Miyazaki H., Matsuoka H., Cooke J.P., et al. Endogenous nitric oxide synthase inhibitor, a novel marker of atherosclerosis. Circulation 99 (1999) 1141-1146
12. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
13. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
14. Päivä H., Laakso J., Laine H., et al. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 40 (2002) 1241-1247
15. Majahalme S., Turjanmaa V., Weder A.B., et al. Blood pressure level and variability in the prediction of blood pressure after 5-year follow-up. Hypertension (1996) 725-731
16. Hemminki V., Kähönen M., Tuomisto M.T., et al. Determination of retinal blood vessel diameters and arteriovenous ratios in systemic hypertension: comparison of different calculation formulas. Graefes Arch Clin Exp Ophthalmol 245 (2007) 8-17
17. Wong T.Y., Klein R., Klein B.E.K., et al. Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Surv Ophthalmol 46 (2001) 59-80
18. O'Brien E., Mee F., Atkins N., et al. Accuracy of the SpaceLabs 90207, Novacor Diasys 200, Del Mar Avionics Pressurometer IV and Takeda TM-2420 ambulatory systems according to British and American criteria. J Hypertens 9 (1991) S332-S333
19. O'Brien E., O'Malley K., Mee F., et al. Ambulatory blood pressure measurements in the diagnosis and management of hypertension. J Hum Hypertens 5 (1991) 23-30
20. Devereux R.B., James G.D., and Pickering T.G. What is normal blood pressure? Comparison of ambulatory blood pressure level and variability in patients with normal or abnormal left ventricular geometry. Am J Hypertens 6 (1993) S211-S215
21. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
22. Vishwanathan K., Tackett R.L., Stewart J.T., et al. Determination of arginine and methylated arginines in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 748 (2000) 157-166
23. Folkow B. Structural, myogenic, humoral and nervous factors controlling peripheral resistance. In: Harington M. (Ed). Hypotensive drugs (1956), Pergamon, London 163-174
24. Baumbach G.L., and Heistad D.D. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 13 (1989) 968-972
25. Sharrett A.R., Hubbard L.D., Cooper L.S., et al. Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 150 (1999) 263-270
26. Noon J.P., Walker B.R., Webb D.J., et al. Impaired microvascular dilation and capillary rarefaction in young adults with predisposition to high blood pressure. J Clin Invest 15 (1997) 1873-1879
27. Zoccali C., Bode-Böger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
28. Valkonen V.P., Päivä H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
29. Wong T.Y., Kaminemi A., Klein R., et al. Quantitative retinal venular caliber and risk of cardiovascular disease in older persons: the cardiovascular health study. Arch Intern Med 166 (2006) 2388-2394
30. Wong T.Y., Islam F.M., Klein R., et al. Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA). Invest Ophthalmol Vis Sci 47 (2006) 2341-2350
31. Delles C., Schneider M.P., John S., et al. Angiotensin converting enzyme inhibition and angiotensin II AT 1-receptor blockade reduce the levels of asymmetrical N(g), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 15 (2002) 590-593
32. Päivä H., Laakso J., Kähönen M., et al. Asymmetric dimethylarginine and hemodynamic regulation in middle-aged men. Metabolism 55 (2006) 771-777
33. Päivä H., Lehtimäki T., Laakso J., et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 52 (2003) 303-307
34. Shepherd J.T. Franz Volhard lecture. Increased systemic vascular resistance and primary hypertension: the expanding complexity. J Hypertens 8 Suppl (1990) S15-S27 [Review]